NovaBridge Biosciences ADR(NBP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.44 | Insider Own | 15.47% | Shs Outstand | 115.4M | Perf Week | -9.02% |
| Market Cap | 0.14B | Forward P/E | - | EPS next Y | -7.44% | Insider Trans | -0.87% | Shs Float | 98.0M | Perf Month | -11.36% |
| Enterprise Value | -0.05B | PEG | - | EPS next Q | -0.18 | Inst Own | 19.63% | Short Float | 3.77% | Perf Quarter | -24.37% |
| Income | -0.05B | P/S | - | EPS this Y | -188.1% | Inst Trans | -5.46% | Short Ratio | 8.75 | Perf Half Y | -51.01% |
| Sales | 0.00B | P/B | 0.7 | EPS next 5Y | - | ROA | - | Short Interest | 3.70M | Perf YTD | -69.6% |
| Book/sh | 1.73 | P/C | 0.74 | EPS past 3/5Y | 52.47% - | ROE | - | 52W High | -76.69% ($5.19) | Perf Year | -73.87% |
| Cash/sh | 1.65 | P/FCF | - | Sales past 3/5Y | - | ROIC | -22.73% | 52W Low | 1.68% ($1.19) | Perf 3Y | -0.82% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 37.9% | Gross Margin | - | Volatility(W/M) | 8.9% 5.95% | Perf 5Y | -98.04% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.64 | EPS Q/Q | -112.22% | Profit Margin | - | RSI (14) | 36.24 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.64 | Sales Q/Q | -100% | SMA20 | -8.42% ($1.32) | Beta | 1.7 | Target Price | $9 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/20 | SMA50 | -20.86% ($1.53) | Rel Volume | 0.86 | Prev Close | $1.26 |
| Employees | 30 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | - | SMA200 | -44.92% ($2.2) | Avg Volume(3M) | 0.42M | Price | $1.21 |
| IPO | 2020/1/17 | Option/Short | Yes/Yes | Trades | 1328 | Volume | 363,896 | Change | -3.97% |
🧬 NovaBridge Biosciences is a clinical-stage oncology biotech company targeting global markets, listed in the form of American Depositary Receipts (ADRs). Centered on a next-generation immuno-oncology pipeline that includes bispecific antibodies, the company pursues a platform strategy of in-licensing clinical assets and rapidly advancing them through proof-of-concept.
Over the past 1 year, on the lower side
77% below its 1-year high.
Traded about as much as usual. That is 86% of its average volume.
NBP has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -188.1% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 19.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #330 of 594 in the industry
Based on market cap of $140M.
MSLE#329 Satellos Bioscience Inc $145M PER - NBP#330 NovaBridge Biosciences ADR $140M PER - 
MENS#331 Jyong Biotech Ltd $140M PER - 
CHRS#332 Coherus Oncology Inc $139M PER - 
CMPX#333 Compass Therapeutics Inc $136M PER - 
FAQ
What kind of company is NBP?
NBP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NBP?
The market cap of NBP is approximately $140M, ranking 4,275 within its sector.
What is the 52-week high and low for NBP?
NBP has recorded a 52-week high of $5.19 and a low of $1.19.
